Key result
The CYP11B2 -344T/C polymorphism did not significantly predict reductions in blood pressure, albuminuria, or GFR decline (P=0.5) in diabetic nephropathy patients treated with losartan.
Why the study?
Does the CYP11B2 -344T/C polymorphism predict the renoprotective and blood pressure lowering response to losartan in hypertensive type-1 diabetic patients with diabetic nephropathy?
Cohort (n=57)
Does the CYP11B2 -344T/C polymorphism predict the renoprotective and blood pressure lowering response to losartan in hypertensive type-1 diabetic patients with diabetic nephropathy?
p-value: p=0.5
The CYP11B2 -344T/C polymorphism does not significantly predict the blood pressure or renoprotective response to losartan in type-1 diabetic patients with diabetic nephropathy.
CYP11B2 -344T/C genotyping should not guide losartan therapy in diabetic nephropathy; leaves open other genetic predictors of ARB response.
No takes yet. Share an insight, caveat, or question.
Schjoedt et al. (2006) conducted a cohort in hypertensive type-1 diabetic patients with diabetic nephropathy (n=57). CYP11B2 -344T/C polymorphism vs. Between genotypes (TT, CT, CC) was evaluated on rate of decline in GFR (p=0.5). The CYP11B2 -344T/C polymorphism did not significantly predict reductions in blood pressure, albuminuria, or GFR decline (P=0.5) in diabetic nephropathy patients treated with losartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: